GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » ROC (Joel Greenblatt) %

Kodiak Sciences (Kodiak Sciences) ROC (Joel Greenblatt) % : -133.48% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kodiak Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -133.48%.

The historical rank and industry rank for Kodiak Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:

KOD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2757.02   Med: -645.24   Max: -152.59
Current: -152.59

During the past 8 years, Kodiak Sciences's highest ROC (Joel Greenblatt) % was -152.59%. The lowest was -2757.02%. And the median was -645.24%.

KOD's ROC (Joel Greenblatt) % is ranked better than
62.45% of 1470 companies
in the Biotechnology industry
Industry Median: -338.875 vs KOD: -152.59

Kodiak Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 43.70% per year.


Kodiak Sciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Kodiak Sciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences ROC (Joel Greenblatt) % Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -2,439.20 -326.18 -285.68 -298.27 -179.16

Kodiak Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -241.75 -182.97 -168.34 -108.39 -133.48

Competitive Comparison of Kodiak Sciences's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Kodiak Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kodiak Sciences's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's ROC (Joel Greenblatt) % falls into.



Kodiak Sciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.259) - (61.759 + 0 + 0)
=-56.5

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.802) - (31.959 + 0 + 0)
=-28.157

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Kodiak Sciences for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-238.064/( ( (181.669 + max(-56.5, 0)) + (175.023 + max(-28.157, 0)) )/ 2 )
=-238.064/( ( 181.669 + 175.023 )/ 2 )
=-238.064/178.346
=-133.48 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kodiak Sciences  (NAS:KOD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Kodiak Sciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kodiak Sciences (Kodiak Sciences) Business Description

Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
Jason Ehrlich officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth director, 10 percent owner, officer: Chairman, President and CEO 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang officer: See Remarks 2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek director P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016

Kodiak Sciences (Kodiak Sciences) Headlines

From GuruFocus